# Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI

> **NCT04298463** · — · COMPLETED · sponsor: **Aziende Chimiche Riunite Angelini Francesco S.p.A** · enrollment: 184 (actual)

## Conditions studied

- Acute Bacterial Skin and Skin Structure Infection

## Interventions

- **DRUG:** Xydalba
- **DRUG:** vancomycin, teicoplanin or daptomycin

## Key facts

- **NCT ID:** NCT04298463
- **Lead sponsor:** Aziende Chimiche Riunite Angelini Francesco S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2022-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298463, "Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04298463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*